Van de Velde V, Crabbe R, Van Peer A, Woestenborghs R, Van Osselaer N, Hantson L, Heykants J
Janssen Research Foundation, Beerse, Belgium.
Int J Clin Pharmacol Ther. 1998 Sep;36(9):490-3.
The single-dose pharmacokinetics of lubeluzole were investigated in 2 single-blind, placebo-controlled, dose-escalation studies in healthy male subjects. In the first study, 6 subjects received an intravenous infusion of 2.5, 5, and 10 mg lubeluzole. In the second study, a 15 mg dose of lubeluzole was administered to 6 subjects, of whom 5 also received 20 mg and 2 also 25 mg lubeluzole. Following the infusion, plasma lubeluzole concentrations decayed biphasically, with a mean distribution half-life (t1/2alpha) of 30 to 65 minutes and a mean terminal half-life (t1/2beta) of 15 to 24 hours. The results of the 2 studies indicate that lubeluzole exhibits linear kinetics over the dose range tested in healthy male subjects.
在两项针对健康男性受试者的单盲、安慰剂对照、剂量递增研究中，对鲁贝唑的单剂量药代动力学进行了研究。在第一项研究中，6名受试者接受了2.5毫克、5毫克和10毫克鲁贝唑的静脉输注。在第二项研究中，给6名受试者服用了15毫克剂量的鲁贝唑，其中5名还接受了20毫克鲁贝唑，2名还接受了25毫克鲁贝唑。输注后，血浆鲁贝唑浓度呈双相衰减，平均分布半衰期（t1/2α）为30至65分钟，平均终末半衰期（t1/2β）为15至24小时。两项研究的结果表明，在健康男性受试者测试的剂量范围内，鲁贝唑呈现线性动力学。
